Dublin, Jan. 15, 2019 (GLOBE NEWSWIRE) — The “Active Pharmaceutical Ingredient/ API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx), Therapy, and Region – Global Forecast to 2024” report has been added to ResearchAndMarkets.com’s offering.
The global APIs market is estimated to reach USD 245.2 billion by 2024 from USD 182.2 billion in 2019, at a CAGR of 6.1% during the forecast period.
The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.
The biotech APIs segment is expected to grow at the highest CAGR during the forecast period.
On the basis of type of synthesis, the APIs market is categorized into synthetic APIs and biotech APIs. The synthetic APIs segment is estimated to account for the largest share in 2019. However, the biotech APIs segment is expected to grow at a higher rate over the forecast period. Factors such as growing demand of biotech drugs due to their specificity in action, advancements in biotechnology, increase in demand for monoclonal antibodies, and their similarity with the natural biological compounds found in the human body influence the growth of this segment.
The monoclonal antibodies segment is expected to account for the largest share of the global biotech APIs market.
Based on product, the biotech APIs market is segmented into monoclonal antibodies, hormones & growth factors, cytokines, fusion proteins, therapeutic enzymes, recombinant vaccines, and blood factors. In 2019, the monoclonal antibodies segment is estimated to account for the largest share of the biotech APIs market. Factors such as the increasing incidence of cancer, increasing investments in R&D, technological advances in genetic sequencing and target gene selection, and reduced side effects as compared to chemotherapy are responsible for driving this market.
North America to dominate the market during the forecast period.
In 2019, North America is expected to dominate the market, followed by Europe. The major factors driving the overall growth of the APIs market in this region include the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. This market segment is expected to grow at a modest rate due to a combination of economic and healthcare severity measures and the introduction of low-cost, generic versions of branded drugs.
Key Topics Covered:
1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology
2.1 Research Data
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation
2.5 Assumptions for the Study
3 Executive Summary
4 Premium Insights
4.1 Active Pharmaceutical Ingredients: Market Overview
4.2 Active Pharmaceutical Ingredients Market, By Type
4.3 Active Pharmaceutical Ingredients Market, By Type of Manufacturer
4.4 Active Pharmaceutical Ingredients Market, By Type of Synthesis
4.5 Active Pharmaceutical Ingredients Market, By Type of Drug
4.6 Geographic Snapshot: Active Pharmaceutical Ingredients Market
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Incidence of Chronic Diseases
5.2.1.2 Technological Advancements in API Manufacturing
5.2.1.3 Growing Importance of Generics
5.2.1.4 Increasing Uptake of Biopharmaceuticals
5.2.1.5 Growing Adoption of Artificial Intelligence-Based Tools for Drug Discovery
5.2.1.6 Adoption of Organ-On-Chip Models in Drug Development
5.2.1.7 Growing Focus on Precision Medicine
5.2.1.8 Growing Investments in Real-World Evidence By Pharmaceutical Companies
5.2.2 Restraints
5.2.2.1 Unfavorable Drug Price Control Policies Across Various Countries
5.2.2.2 Increasing Penetration of Counterfeit Drugs
5.2.3 Opportunities
5.2.3.1 Emerging Biosimilars Market
5.2.3.2 Highly Potent Active Pharmaceutical Ingredients
5.2.3.3 Emerging Markets
5.2.3.4 Emerging Technologies
5.2.4 Challenges
5.2.4.1 Product Differentiation – A Major Concern for API Manufacturers
5.2.4.2 High Manufacturing Costs
6 Active Pharmaceutical Ingredients Market, By Type
6.1 Introduction
6.2 Innovative Active Pharmaceutical Ingredients
6.2.1 Growing Number of New Molecular Entities Gaining Regulatory Approval to Drive Market Growth
6.3 Generic Active Pharmaceutical Ingredients
6.3.1 Government Initiatives Supporting the Adoption of Generic Drugs to Boost Market Growth
7 Active Pharmaceutical Ingredients Market, By Type of Manufacturer
7.1 Introduction
7.2 Captive API Manufacturers
7.2.1 High Manufacturing Flexibility and Assurance of Product Quality Have Driven Focus on Captive Manufacturing
7.3 Merchant API Manufacturers
7.3.1 Merchant API Manufacturers Market, By Type
7.3.1.1 Merchant Innovative API Manufacturers
7.3.1.1.1 Impending Patent Expiries and Increasing Costs of Innovative Drugs May Restrain Market Growth
7.3.1.2 Merchant Generic API Manufacturers
7.3.1.2.1 Low Manufacturing Cost of Generics Likely to Drive the Growth of This Segment
7.3.2 Merchant API Manufacturers Market, By Type of Synthesis
7.3.2.1 Merchant Synthetic API Manufacturers
7.3.2.1.1 Need for Specialized Manufacturing Capabilities has Resulted in Expansion Among Market Players in This Segment
7.3.2.2 Merchant Biotech API Manufacturers
7.3.2.2.1 Complexity of Manufacturing Biotech APIs has Driven Focus on Partnerships Between Companies and CMOS
8 Active Pharmaceutical Ingredients Market, By Type of Synthesis
8.1 Introduction
8.2 Synthetic Active Pharmaceutical Ingredients
8.2.1 Synthetic Active Pharmaceutical Ingredients Market, By Type
8.2.1.1 Innovative Synthetic APIs
8.2.1.1.1 The High Value of Innovative APIs to Drive the Growth of This Segment
8.2.1.2 Generic Synthetic APIs
8.2.1.2.1 Initiatives to Promote the Penetration of Generics to Bring Down Healthcare CostsA Major Growth Driver
8.3 Biotech Active Pharmaceutical Ingredients
8.3.1 Biotech Active Pharmaceutical Ingredients Market, By Type
8.3.1.1 Innovative Biotech APIs
8.3.1.1.1 Growing Demand for Innovative Biopharmaceuticals to Drive the Market for This Segment
8.3.1.2 Generic Biotech APIs
8.3.1.2.1 Increasing Demand for Biosimilar Drugs Due to Their Cost-Effectiveness to Drive the Growth of This Segment
8.3.2 Biotech Active Pharmaceutical Ingredients Market, By Product
8.3.2.1 Monoclonal Antibodies
8.3.2.1.1 Growing Applications of Antibody-Drug Conjugates in the Treatment of Cancer to Drive the Growth of This Segment
8.3.2.2 Hormones & Growth Factors
8.3.2.2.1 The Growing Incidence of Hormonal Disorders to Drive the Market for This Segment
8.3.2.3 Cytokines
8.3.2.3.1 Interferons and Interleukins Boost the Immune System and Have Important Applications in Cancer Treatment
8.3.2.4 Fusion Proteins
8.3.2.4.1 Growing Applications of Fc Fusion Proteins in Biopharmaceuticals to Drive the Growth of This Segment
8.3.2.5 Recombinant Vaccines
8.3.2.5.1 Growing Prevalence of Infectious Diseases has Boosted Vaccine DevelopmentA Positive Indicator of Growth
8.3.2.6 Therapeutic Enzymes
8.3.2.6.1 Growing Significance of Enzymes in Therapies for Cancer and Pain Management to Drive the Growth of This Segment
8.3.2.7 Blood Factors
8.3.2.7.1 Growing Incidence of Hemophilia to Drive the Growth of This Segment
8.3.3 Biotech Active Pharmaceutical Ingredients Market, By Expression System
8.3.3.1 Mammalian Expression Systems
8.3.3.1.1 Ability of These Systems to Carry Post-Translational Modification to Drive the Market for This Segment
8.3.3.2 Microbial Expression Systems
8.3.3.2.1 Ability of These Expression Systems to Provide High Expression Levels of Proteins to Drive the Market for This Segment
8.3.3.3 Yeast Expression Systems
8.3.3.3.1 Advantages Such as Efficient Protein Secretion, Simple Purification, and Endotoxin-Free Products to Boost Demand
8.3.3.4 Insect Expression Systems
8.3.3.4.1 Efficient Post-Translational Modifications Provided By These Systems to Boost Their Demand
8.3.3.5 Other Expression Systems
9 Active Pharmaceutical Ingredients Market, By Type of Drug
9.1 Introduction
9.2 Prescription Drugs
9.2.1 Growing Disease Prevalence is Expected to Drive the Prescription Drugs Market
9.3 Over-The-Counter Drugs
9.3.1 Sales of Otc Drugs Have Risen Due to Innovations, Promotion of Self-Medication, and Increased Access
9.4 Active Pharmaceutical Ingredients Market, By Potency
9.4.1 Low-To-Moderate Potency Active Pharmaceutical Ingredients
9.4.2 Potent-To-Highly Potent Active Pharmaceutical Ingredients
10 Active Pharmaceutical Ingredients Market, By Therapeutic Application
10.1 Introduction
10.2 Communicable Diseases
10.2.1 Global Health Impact of Communicable Diseases and Increasing Antimicrobial ResistanceKey Market Drivers
10.3 Oncology
10.3.1 Increase in Global Spending on Cancer Medication to Boost the Market for This Segment
10.4 Pain Management
10.4.1 Increasing Demand for Innovative and Advanced Pain Medications is A Major Growth Driver for This Market
10.5 Cardiovascular Diseases
10.5.1 Growing Incidence of Cardiovascular Diseases Owing to Sedentary Lifestyles is A Major Growth Driver
10.6 Diabetes
10.6.1 High Global Prevalence of Diabetes to Drive the Growth of This Segment
10.7 Respiratory Diseases
10.7.1 High Global Prevalence of Respiratory Diseases to Drive the Growth of This Segment
10.8 Other Therapeutic Applications
11 Active Pharmaceutical Ingredients Market, By Region
11.1 Introduction
11.2 North America
11.2.1 US
11.2.1.1 Increasing Expenditure on Medicine is Expected to Drive the APIs Market in the Us
11.2.2 Canada
11.2.2.1 Support From Government Organizations is Driving the Growth of the APIs Market in Canada
11.3 Europe
11.3.1 Germany
11.3.1.1 Germany to Dominate the Market in Europe
11.3.2 France
11.3.2.1 Emergence of Pharmerging Markets in Asia May Hinder Market Growth in France
11.3.3 UK
11.3.3.1 Growing Adoption of Generics Will Drive the Growth of the UK Market
11.3.4 Italy
11.3.4.1 Italy’s Share in the Global Merchant APIs Market is Expected to Remain Stable Over the Forecast Period
11.3.5 Spain
11.3.5.1 Spanish Market has Been Typically Dominated By Branded Drugs
11.3.6 Rest of Europe
11.4 Asia
11.4.1 Japan
11.4.1.1 Japanese Government Aims to Boost the Use of Generics By 2020
11.4.2 China
11.4.2.1 Government Policies to Increase Medicine Access and Affordability Will Support Market Growth
11.4.3 India
11.4.3.1 India is A Leading Producer of Generics
11.4.4 South Korea
11.4.4.1 Government Initiatives to Introduce Full Medical Coverage for Major Chronic Diseases Likely to Drive This Market
11.4.5 Rest of Asia
11.5 Rest of the World
12 Competitive Landscape
12.1 Overview
12.2 Market Player Ranking
12.3 Competitive Leadership Mapping
12.3.1 Vanguards
12.3.2 Dynamic Differentiators
12.3.3 Innovators
12.3.4 Emerging Players
12.4 Competitive Situation and Trends
12.4.1 Product Launches
12.4.2 Expansions
12.4.3 Acquisitions
12.4.4 Other Strategies
13 Company Profiles
13.1 Pfizer, Inc.
13.2 Novartis AG
13.3 Sanofi
13.4 Boehringer Ingelheim
13.5 Bristol-Myers Squibb
13.6 Teva Pharmaceutical Industries Ltd.
13.7 Eli Lilly and Company
13.8 Glaxosmithkline PLC
13.9 Merck & Co., Inc.
13.10 Abbvie Inc.
13.11 F. Hoffmann-La Roche
13.12 Astrazeneca
For more information about this report visit https://www.researchandmarkets.com/research/5fw6rr/245_billion?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Pharmaceutical Intermediates
